共 22 条
- [1] Rafii S(2002)Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2 826-835
- [2] Lyden D(2003)Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells Nat. Med. 9 1370-1376
- [3] Benezra R(2006)The multifaceted circulating endothelial cell in cancer: towards marker and target identification Nat. Rev. Cancer 6 835-845
- [4] Hattori K(2006)Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nat. Clin. Pract. Oncol. 3 24-40
- [5] Heissig B(2001)Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma Cancer Res. 61 4341-4344
- [6] Aicher A(2001)Resting and activated endothelial cells are increased in the peripheral blood of cancer patients Blood 97 3658-3661
- [7] Bertolini F(2006)Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy J. Clin. Oncol. 24 1449-1453
- [8] Shaked Y(2007)Reply to: Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay? J. Clin. Oncol. 25 e3-e5
- [9] Mancuso P(2004)Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat. Med. 10 145-147
- [10] Kerbel RS(2005)Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J. Clin. Oncol. 23 8136-8139